The Priority Review

Tag

everolimus

1 story

Stories

  1. Approvals

    FDA approves giredestrant with everolimus for ESR1-mutated breast cancer

    On November 16, 2026 the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify ESR1 mutations.